1. A PHASE 2B RANDOMIZED STUDY OF SINGLE AGENT SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). (June 2017) Authors: Casasnovas, R.; Westin, J.; Thieblemont, C.; Zijlstra, J.; Hill, B.; De La Cruz Vicente, F.; Choquet, S.; Caimi, P.; Kaplan, J.; Canales, M.; Kuruvilla, J.; Follows, G.; van den Neste, E.; Meade, J.; Wrigley, B.; Devlin, M.; Saint‐Martin, J.; Nippgen, C.; Gardner, H.; Shacham, S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 191 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT‐301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL). (12th June 2019) Authors: Collins, G.; Horwitz, S.; Hamadani, M.; Samaniego, F.; Spira, A.; Caimi, P.; Davies, A.; Menne, T.; Fields, P.; Cruz, H.; He, S.; Boni, J.; Feingold, J.; Wuerthner, J.; Radford, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. ANALYSIS OF EFFICACY AND SAFETY OF LONCASTUXIMAB TESIRINE (ADCT‐402) BY DEMOGRAPHIC AND CLINICAL CHARACTERISTICS IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. (12th June 2019) Authors: Radford, J.; Kahl, B.; Hamadani, M.; Carlo‐Stella, C.; O'Connor, O.A.; Ardeshna, K.M.; Feingold, J.; He, S.; Reid, E.; Solh, M.; Chung, K.; Heffner, L.; Ungar, D.; Caimi, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 93 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. ONGOING PHASE 1/2 STUDY OF INCB050465, A SELECTIVE PI3Kδ INHIBITOR, FOR THE TREATMENT OF PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B‐CELL MALIGNANCIES (CITADEL‐101). (June 2017) Authors: Caimi, P.; Ramchandren, R.; Phillips, T.J.; Wertheim, M.S.; Gutierrez, M.E.; Edenfield, W.J.; Akard, L.P.; Call, J.A.; Persky, D.O.; DeMarini, D.J.; Zhou, L.; Yeleswaram, S.; Forero‐Torres, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 268 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL). (23rd June 2022) Authors: Carlo-Stella, C.; Ansell, S.; Zinzani, P. L; Radford, J.; Maddocks, K.; Pinto, A.; Collins, G. P.; Bachanova, V.; Bartlett, N.; Bence-Bruckler, I.; Hamadani, M.; Kline, J.; Mayer, J.; Savage, K. J.; Advani, R.; Caimi, P.; Casasnovas, R.-O.; Feldman, T.; Hess, B.; Bastos-Oreiro, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗